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Abstract In order to translate preclinical data into
the clinical studies, relevant in vitro models with
structure and key functional properties similar to
native human tissue should be used. In vitro cardiac
models with vascular structures mimic the highly
vascularized myocardium and provide interactions
between endothelial cells, stromal cells and cardiomy-
ocytes. Currently, human pluripotent stem cell-
derived cardiomyocytes (hPSC-CMs) have been
shown to present immature morphology and fetal-like
electrophysiological properties that may limit their use
as physiological test platform. The aim of this study
was to develop multicellular in vitro cardiovascular
construct modeling human heart tissue. In the cardio-
vascular construct, hPSC-CMs were cultured with a
vascular-like network formed by human foreskin
fibroblasts and human umbilical vein endothelial cells
that served as a platform in the construct. Cardiomy-
ocyte orientation, maturation, electrophysiological
properties and drug responses of the cardiovascular
construct were characterized and compared to CM
monoculture. hPSC-CMs in cardiovascular construct
showed elongated morphology and aligned with the
vascular-like network. Electrophysiological properties
and calcium metabolism of hPSC-CMs as well as
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response to E-4031 and adrenaline demonstrated
normal physiological behavior. Increased expression
of cardiac structural proteins and ion channels in
cardiovascular construct compared to CM monocul-
ture were detected. In conclusion, vascular-like net-
work supports the structural and functional maturation
of hPSC-CMs. Our results suggest that cardiovascular
construct presents more mature in vitro cardiac model
compared to CM monoculture and could therefore
serve as an advanced test system for cardiac safety and
efficacy assessment as well as a model system for
biomedical research.
Keywords Cardiomyocytes  Vascular-like
network  Maturation
Introduction
In adult heart, the majority of cardiac cells are
highly adaptive cells including fibroblasts, vascular
smooth muscle cells and endothelial cells. 20–40%
of the cardiac cells are cardiomyocytes (Soonpaa
and Field 1998; Brutsaert 2003). In cardiac microen-
vironment, cardiomyocytes are embedded in aligned
extracellular matrix (ECM) that facilitates the coor-
dinated contractile function of the heart (Chien et al.
2008). Cells and ECM proteins, mainly produced by
fibroblasts, are connected via cell–cell and cell–
matrix interactions to maintain the structural orga-
nization and functionality of the heart (van Spreeu-
wel et al. 2014; Pfannkuche et al. 2010b). In mature
myocardium, each cardiomyocyte has physical con-
tact with at least one capillary blood vessel (Garzoni
et al. 2009). The interactions between vasculature
and myocardium are bidirectional (Bhattacharya
et al. 2006), and active throughout the adult life
affecting cardiac growth, function and rhythm
(Brutsaert 2003). From the onset of the cardiac
development, endothelial cells are the prerequisite
for myocardial maturation, physiological function
and survival (Brutsaert 2003). Endothelial cells and
cardiomyocytes interact with each other with para-
crine signals during heart development and activate
the development of cardiac structure. This interac-
tion is required for proper development of endo-
cardium and myocardium. Vascular endothelial cells
produce several compounds including angiopoietin 2
(Ang-2), whereas angiopoietin 1 (Ang-1) and vas-
cular endothelial growth factor (VEGF) are mainly
produced by cardiomyocytes (Brutsaert 2003;
Leucker et al. 2011; Hsieh et al. 2006). In addition,
fibroblasts secrete factors with autocrine and para-
crine effects, such as VEGF, fibroblast growth
factors (FGFs) and transforming growth factor beta
(TGF-b), that give mechanical support and promote
the organization of cardiomyocytes into 3D struc-
tures in collagen matrices (Pfannkuche et al. 2010b;
Wong et al. 2007).
Cardiotoxicity is one of the leading causes of
failure for a new therapeutic molecule preclinical
development (Braam et al. 2010). Presently, pharma-
ceutical industry relies upon animal testing, although
there are fundamental differences in the electrophys-
iological properties of animal and human cardiomy-
ocytes (Feric and Radisic 2016). In particular, the
differences in ion channels and currents impact the
poor predictivity of drug screening and toxicity studies
frommurine to humans (Polini et al. 2014). In addition
to animal models, transfected non-cardiac cells have
been used in preclinical testing. However, these cells
express usually only one cardiac ion channel and lack
other characteristics of human cardiomyocytes. Trans-
fected non-cardiac cells lack a cardiac intracellular
environment that includes cardiomyocyte specific
accessory proteins, as well as, cell structure (Martin
et al. 2004). Therefore, there is an unmet need for
improved human cardiomyocyte model for preclinical
drug screening especially for assessment of car-
diotoxic effects and for evaluation of the efficacy of
new drug candidates (Feric and Radisic 2016; Ketten-
hofen and Bohlen 2008). The cell model should mimic
effectively human cardiomyocytes for example in
terms of cell structure, cardiac specific ion channels
and electromechanical function.
Functional cardiomyocytes derived from human
pluripotent stem cells could provide a significant
advantage over the previously used test systems.
Human pluripotent stem cell derived cardiomyocytes
(hPSC-CMs) contract spontaneously and respond
appropriately to cardioactive drugs (Robertson et al.
2013). These cells could be useful in early efficacy and
toxicity screening, improving the selection of lead
candidates and the reduction of adverse outcomes in
clinical stages of drug development (Davila et al.
2004). According to their morphological and func-
tional characteristics, hPSC-CM have been shown to
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display properties typical to human fetal cardiomy-
ocytes which may complicate their utilization and
interpretation of the obtained results (Snir et al. 2003;
Robertson et al. 2013). Compared to the human adult
cardiomyocytes the hPSC-CMs have been reported to
have lower expression of the genes related to the ion
transportation, calcium handling and sarcomere struc-
ture (Yang et al. 2014). Furthermore, the morphology
of the hPSC-CMs does not resemble the well-aligned
rod-like nature of adult human cardiomyocytes.
Therefore, the maturation level of hPSC-CMs can be
assessed by measuring the expression levels of genes
encoding sarcomeric proteins such as cardiac Tro-
ponin I and T as well as a- and bmyosin heavy chains.
In addition, the expression levels of the cardiac
specific ion channels and connexin 43 responsible
for the intracellular communication can be used in
estimation of the maturation state (Sartiani et al.
2007). In addition to the increased time in culture,
electrical stimulation (Chan et al. 2013) and 3D
culture environment (Schaaf et al. 2011; van Spreeu-
wel et al. 2014; Garzoni et al. 2009; Valarmathi et al.
2010; Pontes Soares et al. 2012) have been utilized in
the production of more mature hPSC-CMs. However,
the use of scaffolds to enable 3D environment has been
associated with reduced cell–cell contacts, as well as
incorrect deposition and alignment of extracellular
matrix in cardiac constructs (Norotte et al. 2009).
In this study, a multicellular in vitro cardiovascular
construct was developed. In the construct, hPSC-CMs
were cultured with vascular-like network composed of
human fibroblasts and human umbilical vein endothe-
lial cells (HUVEC). Vascular-like network serves as a
supporting platform to create natural microenviron-
ment, i.e. biological scaffold, with cell–cell and cell–
matrix interactions. The effects of the vascular-like
network on cardiomyocyte morphology, gene expres-
sion and functionality were studied. Results demon-
strated that the vascular-like network enhanced the
structural maturation and increased the expression
levels of cardiac ion channels in hPSC-CMs in the
cardiovascular construct. Our study suggests that this
cardiovascular construct provides a more mature
in vitro cardiac model compared to CM monoculture
and could therefore serve as an advanced test system
for cardiac safety and efficacy assessment as well as a
model system in biomedical research.
Materials and methods
Ethics
This study conforms to the principles outlined in the
Declaration of Helsinki. The use of human umbilical
vein endothelial cells (HUVEC) and induced pluripo-
tent stem cells (iPSC) were approved by Ethics
Committee of the Pirkanmaa Hospital District, Tam-
pere, Finland (Approval Numbers R08028 and
R08070, respectively) and a written informed consent
was obtained from all the participants.
Cell culture and differentiation
Isolation and culture of human umbilical vein
endothelial cells
HUVECs were isolated from human umbilical cord
vein by using enzymatic procedure as described
previously by us (Sarkanen et al. 2011). Cells were
detached from umbilical cords with 0.05% collage-
nase I, cultured in EGM-2 medium (Lonza Group Ltd,
Basel, Switzerland, Table 1) and tested for myco-
plasma contamination (MycoAlert Mycoplasma
Detection Kit, Lonza Group Ltd) before experimental
use. We use HUVEC as a standard source of
endothelial cells in cell culture studies in our labora-
tory. The isolation and culture process of HUVECs has
been established and validated producing cell lines
with low variability (Sarkanen et al. 2011). Cells are
routinely stored in liquid nitrogen in passage 2 and
used for establishing cell culture models in passage 4.
Each HUVEC line is derived from a single donor and
quality tested routinely for their ability to form tubule
structures in cell culture.
Culture of human foreskin fibroblasts
Human foreskin fibroblasts were purchased from
American Type Culture Collection (BJ, CRL-2522;
ATCC, Manassas, VA, USA). Cells were cultured in
fibroblast medium (Table 1) consisting of Minimum
Essential Medium with Earle’s salts, w/o L-glutamine
(Gibco, Vantaa, Finland) supplemented with 10% FBS
(Gibco), 1% L-glutamine (Gibco) and 1% NEAA
(Gibco). Cells were tested for mycoplasma
Cytotechnology (2017) 69:785–800 787
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contamination (MycoAlert Mycoplasma Detection
Kit, Lonza) before experimental use.
Generation of patient-specific iPSC line and cell
culture of pluripotent stem cells
In this study one commercial human embryonic stem
cell (hESC) line H7 purchased from WiCell Research
Institute (Madison, WI, USA) and one iPSC line was
used for cardiomyocyte differentiation. Patient-speci-
fic iPSC line UTA.04602.WT was established from a
healthy individual as described earlier (Takahashi
et al. 2007). Shortly, skin biopsy from the donor was
cultured in 0.2% gelatin (Sigma-Aldrich, Espoo,
Finland) coated flask under fibroblast culturing con-
ditions. iPSC line was established using lentivirus
infection followed by retrovirus infection (Takahashi
et al. 2007). Cells, plasmids and reagents used in this
protocol include: 293FT cells, Plat-E cells, pLenti6/
UbC/mSlc7a1-vector (Addgene, Cambridge, MA,
USA), ViraPowerTM Packaging Mix (Life Technolo-
gies Ltd), LipofectamineTM 2000 (Life Technologies
Ltd, Vantaa, Finland), Fugene 6 (Roche Diagnostics,
Mannheim, Germany), and pMX retroviral vectors
(hOCT3/4, hSOX2, hKLF4 and hc-MYC, all from
Addgene). Results of the characterization of
UTA.04602.WT cell line have been described earlier
(Lahti et al. 2012).
UTA.04602.WT cells and H7 hESCs were cultured
on mitomycin C inactivated mouse embryonic fibrob-
lasts (MEF) in KSR medium which consisted of
DMEM/F-12 (Invitrogen) supplemented with 20%
KnockOut serum replacement (Invitrogen), 1% non-
essential amino acids (Lonza), 2 mM Glutamax
(Invitrogen), 50 U/ml penicillin/streptomycin
(Lonza), 0.1 mM beta mercaptoethanol (Invitrogen)
and 7.8 ng/ml basic fibroblast growth factor (R&D
Systems). The medium was refreshed daily, and the
stem cell colonies were passaged onto a new MEF
layer once a week using 1 mg/ml collagenase IV
(Invitrogen).
Differentiation of cardiomyocytes
Differentiation of pluripotent stem cells into car-
diomyocytes was carried out with either by co-
culturing hESC or iPSC with murine visceral endo-
derm-like (END-2) cells (Humbrecht Institute,
Utrecht, The Netherlands) as described earlier (Mum-
mery et al. 2003) or with small molecule differenti-
ation method via temporal modulation of canonical
Wnt signaling (Lian et al. 2013). Briefly, in END-2
method undifferentiated hPSC colonies were dissected
mechanically into aggregates and plated on top of
mitomycin C (Tocris) treated END-2 cells in the hPSC
medium. The culture medium was supplemented with
2.92 mg/ml of ascorbic acid (Sigma-Aldrich). The
medium was refreshed on days 5, 8 and 12. On day 14,
10% serum replacement was added to the medium.
Briefly, for small molecule differentiation hPSCs
maintained on a Geltrex-coated surface in mTeSR1
(Stemcell Technologies, Cologne, Germany) were
dissociated into single cells with Accutase (Life
Technologies) at 37 C for 5 min and then seeded
onto a Geltrex-coated cell culture dish at 50,000 cell/
cm2 in mTeSR1 supplemented with 5 lM ROCK
inhibitor (Tocris, Minneapolis, MN, USA) for 24 h.
Cells were then cultured in mTeSR1, changed daily.
On differentiation day 0, medium was exchanged with
RPMI medium (Life Technologies) with 19 B27
Table 1 Culture media used for development of cell models
Acronym Basal
medium
Serum Growth factors Supplementation
Fibroblast medium MEM 10% FBS – 1% L-glutamine, 1% NEAA
EGM-2 medium EBM-2 2% FBS VEGF, FGF-2,
IGF, EGF
Hydrocortisone, ascorbic
acid, heparin
Angiogenic stimulation medium EBM-2 2% FBS 10 ng/ml VEGF,
1 ng/ml FGF-2
1% L-glutamine
EB 5% DMEM/F12 5% FBS – 1% NEAA,
1% Glutamax,
0.5% Pen/Strep
VEGF vascular endothelial growth factor, FGF-2 fibroblast growth factor 2, EGF epidermal growth factor
788 Cytotechnology (2017) 69:785–800
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Supplement minus insulin (Life Technologies) with
10 lM CHIR99021 (Stemgent, Lexington, MA,
USA). 24 h later, medium was exchanged with
RPMI/B27 without insulin. On day 3, medium was
exchanged with RPMI/B27 without insulin supple-
mented with 5 lM IWP4 (Miltenyi Biotech, Bergisch
Gladbach, Germany). On day 5, medium was
exchanged with RPMI/B27 without insulin. On day
7 and every 3 days following, medium was exchanged
with RPMI/B27.
Both differentiation methods formed beating car-
diomyocyte aggregates. These were mechanically
excised and treated with collagenase A (Roche
Diagnostics) to dissociate beating aggregates to single
cell level (Mummery et al. 2003). In each experiment,
cardiomyocytes plated on the monoculture and on top
of the vascular-like network originated from the same
differentiation and dissociation batch.
Development of cell models
Human cardiomyocyte monoculture
After dissociation, human hPSC-CMs were seeded in
EB 5% medium (Table 1) at density of
0.01–0.04 9 106 cells/cm2 in 0.1% gelatin type A
(Sigma-Aldrich) coated 48-well plates for immuno-
cytochemical and qRT-PCR analyses and in micro-
electrode array (MEA) platforms and gelatin coated
12 mm cover slips for functional analyses. EB 5%
medium was changed 1–2 days after cell seeding and
thereafter twice a week. hPSC-CMmonoculture in EB
5% medium was used as a control throughout the
study.
Vascular-like network from co-culture of HUVEC
and fibroblast
The co-culture was established as described earlier
(Sarkanen et al. 2011). Briefly, fibroblasts (p 6–7),
were seeded at 20,000 cells/cm2 in fibroblast medium
(Table 1) in 48-well plates for immunocytochemical
and qRT-PCR analyses and in MEA-platforms and
12 mm diameter cover slips for functional analyses
and grown for 2–3 days to confluency. HUVEC were
seeded on top of confluent fibroblast cultures at
4000 cells/cm2 in EGM-2 medium (Table 1). The
day after cell seeding, angiogenic stimulation medium
containing EBM-2 (Lonza), 2% FBS, 1 mM L-glu-
tamine, 10 ng/ml vascular endothelial growth factor
(VEGF, Sigma) and 1 ng/ml fibroblast growth factor 2
(FGF-2, Sigma) (Table 1) was applied to cells. The
angiogenic stimulation medium was changed twice
during the 6 day co-culture prior to CM seeding.
Cardiovascular construct
EB 5% medium (Table 1) was changed to
HUVEC ? fibroblast co-culture before seeding
hPSC-CMs. Dissociated hiPSC- or hESC-derived
cardiomyocytes in EB 5% medium (Fig. 1) were
seeded on top of the HUVEC ? fibroblast co-culture
at day 6, when the vascular-like network was already
formed, at a density of 0.01–0.04 9 106 cells/cm2 in
48-well plates for immunocytochemical and qRT-
PCR analyses and in microelectrode array (MEA)
platforms and 12 mm diameter cover slips for func-
tional analyses. 1–2 days after cardiomyocyte seeding
first EB medium change was performed and thereafter
Fig. 1 Establishment of
cardiovascular construct
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three times in a week. The viability of cardiovascular
constructs was evaluated visually under microscope
by assessing the contraction of the cardiomyocytes
and vascular-like network formation of the HUVECs
and fibroblasts at least three times in a week.
Medium development
In cardiovascular construct, medium was designed to
primarily support cardiomyocyte functionality and
secondarily to induce vascular-like network forma-
tion. EB medium (Table 1) with different serum
concentrations including 0, 2, 5, 10, and 20% FBS
(Biosera-Immuno Diagnostic Oy, Ha¨meenlinna, Fin-
land) were tested with duplicate wells for dissociated
cardiomyocytes due to our objective to have low-
serum or serum-free culture conditions, to avoid
exogenous bias in our cell culture system and to
develop in vitro model that mimics closely the in vivo
situation in order to improve the predictive value of
the test system. In that, it is important to provide
physiologically relevant environment with low/no-
serum culture conditions. Cells were cultured for
9 days and fixed with 4% PFA (Sigma-Aldrich) for
immunocytochemical stainings with goat-anti-cardiac
troponin-T (anti-Tnt, 1:1500, Abcam, Cambridge,
U.K.). Cells were mounted with Vectashiel (Vector
Laboratories, Burlingame, CA, USA) containing
DAPI for staining nuclei. The results of the serum
concentration tests can be found in the supplemental
data (Fig. S1).
Immunocytochemistry
Cardiomyocytes in CM monoculture and in cardio-
vascular construct were stained either with goat anti-
cardiac-troponin-T (anti-Tnt, 1:1500, Abcam) or with
mouse anti-Tnt (1:500, Abcam) and the vascular-like
formation was visualized with basement membrane
marker mouse collagen IV (anti-ColIV, 1:500, Sigma)
for 1 h at RT or in ? 4 C o/n. Polyclonal IgG Alexa
Fluor 568 (Abcam) for goat anti-Tnt and polyclonal
IgG FITC (1:100, Sigma) for anti-ColIV and mouse
anti-Tnt were used as secondary antibodies for 30 min
in RT. Fluorescence was visualized with Nikon
Eclipse Ti-S microscope (Nikon, Otawara, Tochigi,
Japan) or with confocal laser scanning microscope
Zeiss LSM780 Laser Scanning Confocal Microscope
(ZEISS, Oberkochen, Germany). The images were
processed with Zen2009 (confocal images, Carl Zeiss)
and with Adobe Photoshop software 7.0 (Adobe
Systems). The results are from at least 4 individual
experiments performed in duplicates.
Quantitative real time-PCR
Gene expression in CM monoculture, vascular-like
network and cardiovascular construct were analyzed.
The total RNA was extracted at day 1, 6, 7 and 18
(Fig. 1) using PureLink RNA Mini Kit (Life Tech-
nologies) following the manufacturer’s protocol.
Concentration and purity of RNA was assessed using
spectrophotometry with microplate reader in Var-
ioskan Flash Spectrophotometer (ThermoScientific,
Espoo, Finland) before further use. Reverse transcrip-
tion of the total RNA to cDNA was performed using
iScript cDNA synthesis kit (Bio-Rad, Helsinki, Fin-
land) following manufacturer’s instructions. qRT-
PCR was performed according to standard protocols
on Abi Prism 7300 instrument (Applied Biosystems,
Espoo, Finland) or on Bio-rad CFX96 Real Time
System (BioRad). For each time point two biological
replicate samples were collected and samples were
analyzed as triplicates. The expression of angiogenesis
related genes including VEGF-A, FGF-2, PDGF-b,
TGF-b1, Angiopoietin-1, Angiopoietin-2 and cardiac
related genes including CACNA1C, TNNT2, KCNJ2,
CX43, MYH6, MYH7 were studied with SYBR chem-
istry. In addition, the expression of cardiac related
genes ADRB1 and SCN5a as well as reference gene
GAPDH were studied using Taqman chemistry with
Taqman Universal PCR Master Mix (Applied Biosys-
tems). The following Taqman assays (209) were used:
Hs02330048_s1 for ADRB1, Hs00165693_m1 for
SCN5A and Hs02758991_g1 for GAPDH (Applied
Biosystems). SYBR primer sequences can be found in
supplemental data (Supplementary Table 1). The
relative expression levels were determined by using
the comparative method (DDCt) and GAPDH was
used as an endogenous control (Livak and Schmittgen
2001, 402–408).
Functional analyses
Microelectrode array (MEA) measurements
The ability of cardiovascular construct to conduct
electrical signal was analyzed using the MEA system
790 Cytotechnology (2017) 69:785–800
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(Multi Channel Systems MCS GmbH, Reutlingen,
Germany). The MEA platforms (8 9 8 standard
MEAs or 6-well MEAs) were first hydrophilized with
FBS and then coated with 0.1% gelatin type A (Sigma-
Aldrich).
Field potentials were recorded at day 10 or 18
(Fig. 1) at 37 C, and signals were recorded for 2 min.
The sampling frequency was 20 kHz. Field potentials
were recorded during spontaneous baseline beating,
and with 1 lM adrenaline (Sigma-Aldrich) or 300 nM
E-4031 (Sigma-Aldrich), which were incubated 2 min
before measurements. Drugs were diluted and mea-
surements performed in EB 5% medium. The field
potentials were recorded with MC_Rack v.4.5.7
software (Multi Channel Systems MCS GmbH).
Signals were analyzed with Cardiomyocyte MEA
Data Analysis (CardioMDA) software (Pradhapan
et al. 2013).
Analysis of Calcium2? cycling
Cardiovascular constructs were loaded with 4 lmol/L
Fura-2 AM (Invitrogen, Molecular Probes) for 30 min
in HEPES based medium. Measurements were
assessed in 37 C and the extracellular solution
consisted of (in mmol/L): 137 NaCl, 5 KCl, 0.44
KH2PO4, 20 HEPES, 4.2 NaHCO3, 5 D-glucose, 2
CaCl2, 1.2 MgCl2 and 1 Na-pyruvate (pH was adjusted
to 7.4 with NaOH).
Ca2? measurements were recorded at day 10 or 11
(Fig. 1) and conducted on an inverted IX70 micro-
scope (Olympus Corporation, Vantaa, Finland) with a
UApo/340 209 air objective (Olympus). Images were
acquired with an ANDOR iXon 885 CCD camera
(Andor Technology, Belfast, U.K.) synchronized with
a Polychrome V light source by a real time DSP
control unit and TILLvisION software (TILL Photon-
ics, Gra¨felfing, Germany). Fura-2 in cardiomyocytes
was excited at 340 and 380 nm light and the emission
was recorded at 505 nm. For Ca2? analysis, regions of
interests were selected for spontaneously beating cells
and background noise was subtracted before further
processing. The Ca2? levels are presented as ratio-
metric values of F340/F380. The changes in Ca2?
were recorded during spontaneous baseline beating
and spontaneous beating after 2-min 1 lM adrenaline
(Sigma-Aldrich) perfusion.
Statistics
qPCR data are expressed as mean values ±SD.
Statistical analysis for the qPCR data was performed
by IBM SPPS Statistics 22-software and by using
Mann-Whitney U-test for independent samples. Bon-
ferroni-correction was included when more than two
groups were analyzed. A p value less than 0.05 was
considered statistically significant.
In MEA and Ca2? imaging data, the significance of
differences between the two groups (CM monoculture
and cardiovascular construct) was evaluated with the
unpaired Student’s t test. The significance of changes
within a group was evaluated with the paired Student’s
t test. MEA and Ca2? imaging data are expressed as
average ± SEM. In Ca2? imaging data n refers to the
number of cells and in MEA data n refers to number of
MEA wells. A p value less than 0.05 was considered
statistically significant.
Results
Vascular-like network serves as a supporting
and interactive platform for cardiovascular
construct
Expression levels of angiogenesis related genes were
analyzed at days 1, 6 and 18 in vascular-like network
to assess the production of growth factors and
maturation state of vascular structures (Fig. 2). During
the first six days the expression of fibroblast growth
factor 2 (FGF-2), transforming growth factor b (TGF-
b) and angiopoietin-1 (Ang-1) had an increasing trend
whereas VEGF expression remained constant. Statis-
tically significant increase was observed in angiopoi-
etin 2 (Ang-2) and platelet derived growth factor b
(PDGF-b) expression. During the days 6–18, the
expression of aforementioned genes remained con-
stant except for Ang-2, which had significantly
increased expression level.
The expression levels of the angiogenesis related
genes were also assessed from the cardiovascular
construct at day 6 and 18 (Fig. 2). The expression
levels of FGF-2, TGF-b and angiopoietin-1 remained
quite constant during culture, whereas Ang-2 expres-
sion was decreased in cardiovascular construct
Cytotechnology (2017) 69:785–800 791
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Fig. 2 Relative gene expression levels of angiogenesis related
genes including vascular endothelial growth factor (VEGF),
fibroblast growth factor 2 (FGF-2), transforming growth factor
beta (TGF-b), angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2)
and platelet derived growth factor beta (PDGF-b) in cardiovas-
cular construct and in vascular-like network at time points 1, 6
and 18. The GAPDH was used as a endogenous control.
*p\ 0.05
Fig. 3 Morphology of human pluripotent stem cell derived
cardiomyocytes in a monoculture and in b cardiovascular
construct at day 14 in 10% FBS. Orientation of human
pluripotent stem cell derived cardiomyocytes (troponin T, red)
with vascular-like network (collagen IV, green) in c,
d cardiovascular construct at day 7 in 5% FBS. C Confocal
3D z-stack projection having the scale bars included in the
image. The vertical height is 100 lm and the horizontal length
between two major tick intervals is also 100 lm. In a, b and
d the scale bars represent 50 lm. (Color figure online)
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compared to the vascular-like network. However, the
expression levels of VEGF and PDGF-b were signif-
icantly higher in the cardiovascular construct.
Vascular-like network enhances mature cardiac
phenotype and orientation of pluripotent stem cell
derived cardiomyocytes in cardiovascular
construct
Compared to the round morphology and the random
orientation of cardiomyocytes in monoculture
(Fig. 3a; S1), more mature morphology with elon-
gated cardiomyocytes was detected in the presence of
vascular-like network (Fig. 3b). Moreover, 2D and 3D
projections showed that cardiomyocytes co-localized
longitudinally and parallel with tubular structures
(Fig. 3c, d). On the contrary, cardiomyocytes in
monoculture remained rounded, less organized and
the orientation of the cells along the tubule structures
could not be detected.
The expression levels of cardiac related genes
were analyzed in the cardiovascular construct and in
the CM monoculture at one day after cardiomyocyte
seeding (day 7) and at day 18 (Fig. 4). Results
showed that the expression of cardiac muscle
myosin transcripts MYH6 and MYH7 as well as
cardiac troponin T increased between day 7 and 18
(p\ 0.05) whereas the expression remained con-
stant or decreased in the CM monoculture. The
expression level of gap junction marker connexin 43
was also shown to increase significantly in cardio-
vascular construct (p = 0.002) between day 7–18
while remaining low in the CM monoculture. At day
18 the expression levels of MYH6, MYH7, troponin
T and connexin 43 were all at higher level in the
cardiovascular construct when compared to the CM
monoculture (p\ 0.05) (Fig. 4).
In the cardiovascular construct, the expression
levels of ion channels CACNA1C, KCNJ2 and SCN5A
did not increase significantly between days 7–18
(Fig. 4). However, similarly to structural genes, there
was statistically significant difference when expres-
sion levels were compared between cardiovascular
construct and CM monoculture at day 18. The
Fig. 4 Relative gene expression levels of cardiac related genes
troponin T (TNNT2), cardiac muscle myosins (MYH6, MYH 7),
connexin 43 (Cx43), calcium channel (CACNA1C), potassium
channel (KCNJ2), sodium channel (SCN5A) and beta-1-
adrenergic receptor (ADBR1) at time points day 7 and day 18
in cardiomyocyte monoculture and in cardiovascular construct.
The GAPDH was used as an endogenous control. *p\ 0.05
Cytotechnology (2017) 69:785–800 793
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expression of beta-1 adrenergic receptor (ADRB1)
was significantly higher at day 7 to day 18 in the
cardiac construct (p[ 0.05). Moreover, the
expression was significantly higher at day 18 in the
cardiovascular construct compared to CM
monoculture.
794 Cytotechnology (2017) 69:785–800
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Electrophysiological changes in pluripotent stem
cell derived cardiomyocytes in cardiovascular
construct suggest functional improvement
of the cardiomyocytes
Contractility areas of the cardiovascular model were
large and synchronous and beating was stronger when
compared to moderately beating CM monoculture
with smaller separately beating areas (Video S1, S2
and S3). The electrical activity of the cardiovascular
construct was detectable with MEA and the contrac-
tility was synchronous (Fig. 5a). Adrenaline increased
the beating frequency of cardiomyocytes (Fig. 5b, c)
thus decreasing the field potential duration (FPD) in
cardiovascular constructs as well as in CM monocul-
ture (Fig. 5d). The increase in beating frequency and
decrease in FPD was statistically significant between
baseline and adrenaline only in cardiovascular con-
struct (Fig. 5c, p\ 0.05).
E4031, a hERG blocker, was shown to significantly
prolong the FPD both in cardiovascular construct and
in CM monoculture compared to the baseline (both
p\ 0.05) but there was no significant difference
between the groups (Fig. 5e, f). Prolongation of FPD
due to E4031 exposure resulted in additional adverse
effects including pausing beating and/or arrhythmias.
These adverse effects were seen in CMmonoculture as
well as in cardiovascular construct (Fig. 5g).
Ca2? transients of pluripotent stem cell derived
cardiomyocytes in the absence and presence
of vascular-like network
Cardiovascular construct and CM monoculture were
shown to respond similarly to adrenaline exposure (See
supplemental Fig. S2A). When compared to baseline,
adrenaline caused a significant increase in beating
frequency (Fig. 6d, p\ 0.05) and a decrease in peak
duration in both systems (Fig. 6b) and, additionally, a
significant decrease in amplitude in cardiovascular
construct (Fig. 6c, p\ 0.05). The amplitude in car-
diovascular construct was significantly lower at base-
line as well as during adrenaline perfusion compared to
those in CM monoculture (Fig. 6c, p\ 0.05).
The diastolic Ca2? increased significantly in CM
monoculture and in cardiovascular construct due to the
adrenaline exposure (Fig. 6a, p\ 0.05). Ca2? tran-
sient changes were also analyzed separately for each
cell as the ratio of adrenaline response divided by
baseline response. The results showed that in cardio-
vascular construct adrenaline caused a significant
increase in beating frequency and significant decrease
in amplitude when compared to CM monoculture (see
supplemental Fig. S2B, p\ 0.05).
Discussion
The use of physiologically relevant in vitro model
systems is a prerequisite for translating the preclinical
data into clinical studies (Engle and Puppala 2013). In
preclinical cardiotoxicity studies, the assessment of
the risk for QT interval prolongation is part of the
standard evaluation of new compounds as defined by
the International Conference of Harmonization (ICH)
Expert Working Group (Braam et al. 2010). Human
pluripotent stem cell derived cardiomyocyte (hPSC-
CM) based test systems could improve the early
detection of QT prolongation with the benefit of being
of human origin (Pfannkuche et al. 2010a). However,
it is widely acknowledged that hPSC-CMs possess
fetal-like characteristics, e.g. contractility with prolif-
erative capacity and embryonic-like electrophysiol-
ogy. Although the factors affecting maturity remain
largely unknown, cell line, culture time, culture type
and other culture conditions appear to have effects on
the maturity (Robertson et al. 2013).
bFig. 5 MEAmeasurements of the cardiovascular construct and
CM monoculture. a The electrical activity of the cardiovascular
construct was detectable with MEA and the contractility was
synchronous; b representative field potential traces of the effect
of b-adrenergic agonist adrenaline (1 lM); c beating frequency
and d field potential duration (FPD) of baseline and adrenaline
measurements of CMmonoculture and cardiovascular construct
(both n = 5). e Overlay plot showing the effect of 300 nM
E-4031 on FPD; f the effect of E-4031 on FPDwas calculated as
relative change from the baseline in both CM monoculture
(n = 6) and cardiovascular construct (n = 7). In both of these
FPD was significantly prolonged with E4031 when compared to
baseline but there was no significant difference between CM
monoculture and cardiovascular construct. g Adverse effects of
E-4031 during the time of 2 min measurement. The number
indicates how many replicates were affected. Normal: no
arrhythmias, Normal ? Pause: no arrhythmias but field poten-
tial activity terminates, Arrhythmia: arrhythmias affecting
amplitude and frequency, Arrhythmia ? Pause: arrhythmias
leading to termination of beating activity. CM cardiomyocyte
monoculture, CvC cardiovascular construct. *p\ 0.05
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We have previously developed cardiovascular
constructs based on co-culture of neonatal rat car-
diomyocytes and two different vascular-like networks
formed either by human adipose stromal cells ? HU-
VECs or HUVECs ? fibroblasts. In the previous
study, cardiomyocyte viability and functionality was
maintained longer in co-cultures and morphological
maturation was detected (Vuorenpaa et al. 2014). In
the present study, vascular-like network, formed by
HUVEC and fibroblasts, was combined with human
cardiomyocytes to develop a completely human cell
cardiovascular construct for cardiac safety and effi-
cacy assessment and for biomedical research.
Expressions of cardiac structural protein coding
genes MYH6 and MYH7, cardiac troponin T and gap
junction marker connexin 43 were significantly
increased in cardiovascular construct whereas they
remained constant or decreased in CM monoculture.
In CMmonoculture, the overgrowth of non-cardiomy-
ocytes may explain the decreased expression of
structural transcripts MYH6, MYH7 and troponin T.
However, similar overgrowth of non-cardiomyocytes
was not detected in cardiovascular construct. Similar
results were reported by Caspi et al. (2007) who
showed that genes coding structural proteins were
expressed at higher level when cardiomyocytes were
cultured with endothelial cells and fibroblasts in 3D
biodegradable scaffold. Burridge et al. (2014) reported
that troponin T expression was significantly enhanced
at protein level in the multicellular culture when
compared to the CM monoculture. Our results are in
line with the previous studies, suggesting that vascu-
lar-like network improves the cardiac specific pheno-
type of hPSC-CMs.
In heart, the extracellular matrix, mainly produced
by the cardiac fibroblasts, guides cellular orientation
and organization thus facilitating efficient cell con-
traction, force transduction and electrical transmission
between the cells. Ventricular cardiomyocytes in the
adult human heart are large and brick-shaped whereas
hPSC-CMs are markedly smaller with round or
triangular morphology (Hartman et al. 2015). The
importance of alignment of cardiomyocytes in coor-
dinated contraction is seen in the native cardiac
structure, but is also shown in in vitro studies (van
Spreeuwel et al. 2014). The alignment of cardiomy-
ocytes has been induced in vitro by microcontact
printing, demonstrating that alignment improves
Fig. 6 Ca2? measurements of the cardiovascular construct
(black columns) and cardiomyocyte monoculture (white
columns) in baseline and after adrenaline exposure represented
as a diastolic Ca2? levels; b peak duration; c amplitude and
d frequency. CMmonoculture n = 16, cardiovascular construct
n = 26. *p\ 0.05
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cardiomyocyte calcium handling and contractile prop-
erties when compared to randomly oriented cardiomy-
ocyte monolayers (Pong et al. 2011; Feinberg et al.
2012). Our results demonstrate that seeding of hPSC-
CMs on already formed vascular-like network orien-
tates the hPSC-CMs parallel with the tubule structures.
Moreover, as detected in 3D projection, some hPSC-
CMs are seen to surround the tubule structures.
Fibroblasts are known to produce extracellular matrix
components and enhance alignment of cardiomy-
ocytes (Pfannkuche et al. 2010b). The presence of
fibroblasts is likely to enhance the orientation of
hPSC-CMs with vascular-like structures.
Although earlier studies have shown that co-culture
with endothelial cells and fibroblasts enhances the
formation of more mature-like morphology of car-
diomyocytes and increases the expression of cardiac
specific genes and their electromechanical properties
(Burridge et al. 2014; Radisic et al. 2008; Caspi et al.
2007), they are based on the utilization of different
artificial scaffolds. Since the use of scaffolds in
cardiac constructs has been associated with reduced
cell–cell contacts, as well as incorrect deposition and
alignment of extracellular matrix (Norotte et al. 2009),
we aimed at inducing natural in vitro cardiovascular
construct. We have previously shown that the vascu-
lar-like network formed by HUVEC and fibroblasts
serves as a supporting platform for the rat cardiomy-
ocytes (Vuorenpaa et al. 2014). In the present study,
vascular-like network serves as a natural, supporting
and interactive platform for the hPSC-CMs. Enhanced
maturation of hPSC-CM detected already in 12 days
suggests that the cardiovascular construct provides a
more rapid test system. In addition, we detected
increased sensitivity in response to adrenaline, which
is likely due to higher expression of the b1-adrenore-
ceptor in cardiovascular construct compared to CM
monoculture.
Our current results with hPSC-CMs showed that the
expression of several growth factors including VEGF,
FGF-2, Ang-1, PDGF-b and TGF-b was active in
vascular-like network throughout the experiment. In
cardiovascular construct, expression levels of growth
factors had a similar trend as in the vascular-like
network, except for VEGF and PDGF-b that were
increased in the cardiovascular construct. In vascular
network, when endothelial cells assemble into tubular
structures, endothelial cells start expressing PDGF-B
to recruit PDGF-B receptor positive pericytes to
surround the endothelial structures, a step required
for tubular maturation. Endothelial cells also secrete
PDGF-B and other factors in order to modulate
cardiomyocytes and assist in the development of heart
tissue. As VEGF is mainly produced by the cardiomy-
ocytes (Brutsaert 2003; Leucker et al. 2011), the
increase in the expression level of VEGF at day 18 is in
line with the time in culture. In addition, Ang-2, a
marker of early stage tubule formation that is
expressed when sprouting of tubules and formation
of new tubules occurs, was shown to increase in
vascular-like network suggesting ongoing tubule for-
mation process in vascular-like network. However,
Ang-2 was low in cardiovascular construct, indicating
more mature vascular structures, a result that is also in
line with the increased PDGF-b expression during
culture. Therefore, cardiovascular construct, deprived
of exogenous growth factors, was capable of activat-
ing the growth factor expression and maintain the
differentiation process endogenously.
Our current results suggest that mature vascular-
like structures seem not to be the prerequisite for the
development of functional cardiovascular construct.
More important seems to be the interactive natural
stromal support that endothelial cells and fibroblasts
provide to the construct. These cells induce cardiomy-
ocytes by secreting several growth factors (Brutsaert
2003; Leucker et al. 2011; Pfannkuche et al. 2010b;
Wong et al. 2007) and by providing e.g. endothelial-
cardiomyocyte contacts, known to be crucial in
maintaining the rhythmic and synchronous contraction
of cardiomyocytes (Brutsaert 2003). These cell–cell
and cell–matrix interactions as well as paracrine
signals of the co-cultured cells, seemed to be critical
for the viability of hPSC-CMs and functionality of the
developed cardiovascular construct. Although the
vascular-like network formation and differentiation
cease in the absence of VEGF and FGF-2 during
hPSC-CM culture, the cardiomyocyte viability or
contractility, as detected in the MEA and calcium
metabolism measurements, are enhanced in the pres-
ence of the network.
Although the major ionic currents normally present
in adult cardiomyocytes are expressed also in hPSC-
CMs (Robertson et al. 2013), differences are seen in
the expression levels of cardiac ion channels and in
calcium handling genes (Synnergren et al. 2007). Our
gene expression data showed that in the presence of
vascular-like network, the expression of transcripts of
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sodium (SCN5A) and calcium (CACNA1C) channels
were increased during the days 7–18, while the level of
potassium channel (KCNJ2) remained constant. More
importantly, all these genes were expressed at higher
level in the cardiovascular construct compared to CM
monoculture at the end of the experiment (day 18).
SCN5A gene codes the cardiac sodium channel NaV1.5
which functions in the fast depolarization phase of the
cardiac action potential. The expression level of
SCN5A has been reported to increase when hPSC-
CMs were maturated upon electrical stimulation
(Chan et al. 2013). In addition, the expression of
CACNA1C, gene coding the L-type Ca?-channel Cav
1.2, was shown to increase in co-culture with hESC-
derived endothelial cells and human amniotic mes-
enchymal stem cells (Burridge et al. 2014). The
expression level of KCNJ2 that codes the Kir2.1
channel responsible for the inward rectifier potassium
current (IK1), has been reported to significantly
increase during hESC-CM maturation (Sartiani et al.
2007) and in culture with endothelial cells (Burridge
et al. 2014). Despite the relative short co-culture time
with vascular-like network, cardiomyocytes in car-
diovascular construct expressed these ion channel-
coding genes at higher level compared to CM mono-
culture. The increased expression indicates that the
aforementioned currents are increasingly present in
the cardiovascular construct and the hPSC-CMswould
therefore exhibit electrophysiologically more mature
phenotype than the monoculture of cardiomyocytes.
MEA measurements showed that E-4031 increased
significantly the field potential duration and arrhyth-
mogenicity in the cardiovascular construct as well as
in CM monoculture. Calcium imaging analysis
showed that Ca2? transients were detectable and
adrenaline responses evident in the cardiovascular
construct. We detected that adrenaline increased
significantly the beating frequency of cardiovascular
construct compared to CM monoculture. This was
evident in field potential recordings as well as in Ca2?
cycling measurements and further confirmed by gene
expression analysis. A significantly higher expression
of ADRB1, a gene encoding the b1-adrenoreceptor,
was detected in the cardiovascular construct compared
to CM monoculture which further supports the con-
clusion that vascular-like network has positive effect
on the maturation status of the hPSC-CMs.
The specific mechanism how vascular-like network
enhances the maturation state of hPSC-CMs remains
unknown. Comparative analysis between cardiovas-
cular construct and adult human myocardium could
give more detailed information about the maturation
state of the construct. However, it can be hypothesized
that neighboring non-myocytes could enhance the
electrical maturation of hPSC-CMs in cardiovascular
construct by secreting paracrine factors or non-cardiac
cells might enhance cardiomyocyte signal propagation
through cell-to-cell contacts as also suggested by
others (Sekine et al. 2008; Narmoneva et al. 2004).
Our results suggest that cardiovascular construct
presents a more mature in vitro cardiac model
compared to CM monoculture and could therefore
serve as an advanced test system for cardiac safety and
efficacy assessment as well as a model system for
biomedical research.
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